IRIS
LANDI, DORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.782
AS - Asia 2.425
EU - Europa 1.746
SA - Sud America 398
AF - Africa 33
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.392
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.724
SG - Singapore 1.206
IT - Italia 729
BR - Brasile 329
CN - Cina 318
RU - Federazione Russa 312
HK - Hong Kong 270
VN - Vietnam 199
IE - Irlanda 196
KR - Corea 176
JP - Giappone 102
DE - Germania 96
FR - Francia 70
GB - Regno Unito 66
NL - Olanda 64
FI - Finlandia 36
UA - Ucraina 36
CA - Canada 34
AR - Argentina 26
IN - India 26
SE - Svezia 26
AT - Austria 24
IQ - Iraq 19
TR - Turchia 19
CH - Svizzera 18
BD - Bangladesh 15
ES - Italia 15
EC - Ecuador 14
PL - Polonia 14
ZA - Sudafrica 12
GR - Grecia 11
MX - Messico 11
PK - Pakistan 11
ID - Indonesia 10
EG - Egitto 9
MY - Malesia 9
CZ - Repubblica Ceca 8
CL - Cile 7
CO - Colombia 7
PY - Paraguay 7
UZ - Uzbekistan 7
KG - Kirghizistan 6
RS - Serbia 6
IR - Iran 5
RO - Romania 5
AU - Australia 4
AZ - Azerbaigian 4
PE - Perù 4
PH - Filippine 4
MA - Marocco 3
PA - Panama 3
SA - Arabia Saudita 3
VE - Venezuela 3
AL - Albania 2
DK - Danimarca 2
DZ - Algeria 2
JO - Giordania 2
KE - Kenya 2
NG - Nigeria 2
NI - Nicaragua 2
PT - Portogallo 2
QA - Qatar 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
NZ - Nuova Zelanda 1
OM - Oman 1
SI - Slovenia 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 10.392
Salva come PNG Salva come JPEG
Città #
Wilmington 1.234
Houston 970
Singapore 647
Woodbridge 527
New York 370
San Jose 347
Hong Kong 267
Chandler 198
Fairfield 179
Dublin 177
Ashburn 153
Beijing 135
Rome 100
Santa Clara 92
Tokyo 90
Los Angeles 83
The Dalles 83
Ho Chi Minh City 75
Ann Arbor 65
Dallas 65
Milan 60
Seattle 59
Medford 57
Roebling 55
Moscow 53
Cambridge 50
Buffalo 46
Council Bluffs 46
Hanoi 44
North Bergen 43
São Paulo 39
Lauterbourg 36
Dearborn 29
Lawrence 28
Naples 24
Turin 24
Chicago 21
Lappeenranta 19
San Diego 19
Nuremberg 17
Redondo Beach 16
Colorado Springs 15
Bologna 14
Jacksonville 14
Piove di Sacco 13
Creede 12
London 12
Florence 11
Frankfurt am Main 11
Haiphong 11
Montreal 11
Munich 11
San Francisco 11
Helsinki 10
Jakarta 10
Orem 10
Seoul 10
Tampa 10
Warsaw 10
Belo Horizonte 9
Brooklyn 9
Elk Grove Village 9
Mülheim 9
Palo Alto 9
Vienna 9
Atlanta 8
Bari 8
Brno 8
Inverigo 8
Norwalk 8
Paris 8
Redwood City 8
Salt Lake City 8
Toronto 8
Da Nang 7
Denver 7
Genoa 7
Johannesburg 7
Kuala Lumpur 7
Manchester 7
Palermo 7
Phoenix 7
Rio de Janeiro 7
Amsterdam 6
Belgrade 6
Brasília 6
Chennai 6
Erbil 6
Lodi 6
Mexico City 6
Nanjing 6
Sterling 6
Zhengzhou 6
Athens 5
Billings 5
Boardman 5
Buenos Aires 5
Kilburn 5
Miami 5
Philadelphia 5
Totale 7.132
Salva come PNG Salva come JPEG
Nome #
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 515
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 503
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 440
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 360
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 339
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 334
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 327
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 318
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study 317
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis 313
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 306
null 289
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 201
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis 180
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 179
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 167
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 161
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 155
Functional assessment of outer and middle macular layers in multiple sclerosis 147
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 137
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 132
Assessment of macular function by multifocal electroretinogram in patients with multiple sclerosis treated with fingolimod 122
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 119
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 118
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 111
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 107
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 106
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus 99
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis 97
Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity 95
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey 94
COVID-19: dealing with a potential risk factor for chronic neurological disorders 94
Complex epileptic palilalia: a case report 88
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population 88
Cognition is related to resting-state small-world network topology: an magnetoencephalographic study 86
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 85
What happens after fingolimod discontinuation? A multicentre real-life experience 82
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment 81
A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients 80
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 78
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection 78
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 77
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 77
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 72
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 71
Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study 71
Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment 68
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 68
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 68
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration 68
Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach 67
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability 67
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 67
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 67
Cerebral restorative plasticity from normal ageing to brain diseases: a "never ending story" 66
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 64
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 64
Cortico-muscular coherence as an index of fatigue in multiple sclerosis 63
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 63
Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment 63
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 63
Phenotypic characterization of the placenta from women with Multiple Sclerosis exposed to Natalizumab during pregnancy. 62
Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment 61
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 60
Ovarian reserve in patients with multiple sclerosis: A systematic review and meta-analysis 60
Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis: Association With Linear Versus Macrocyclic Gadolinium-Based Contrast Agents Administration 59
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol 58
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 57
Gender-related differences in functional connectivity in multiple sclerosis 56
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis 56
Sex effects across the lifespan in women with multiple sclerosis 54
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability 54
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 54
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 53
Sars-CoV2 infection in pregnant women with multiple sclerosis 53
A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis 51
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 50
Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience 48
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing???remitting multiple sclerosis 48
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 48
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 47
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey 46
Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report 44
Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop) 43
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areas 42
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data 40
Exposure to natalizumab during pregnancy and lactation is safe - Yes 39
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine 38
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 38
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 37
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 33
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 28
Treatment discontinuation in older patients with multiple sclerosis 26
null 5
null 3
Totale 10.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.405
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202146 0 0 0 0 0 0 0 0 0 0 29 17
2021/2022379 29 28 20 40 23 48 14 22 34 27 23 71
2022/20231.104 38 30 286 193 48 178 119 47 74 12 59 20
2023/2024451 101 10 22 23 32 64 35 12 28 23 11 90
2024/20252.078 61 375 180 142 62 212 144 88 220 273 180 141
2025/20263.123 274 214 397 199 324 99 493 421 392 272 38 0
Totale 10.633